Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,152 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Water control Clear all
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

NCT01179217
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle ß0-Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An RCT Evaluating the Efficacy of a Skincare Routine and Acne Supplement on Improving Acne and Other Symptoms of PMS

NCT06018168
View directory record Official record
Conditions
Acne, Premenstrual Syndrome
Interventions
Skincare Routine, MINDBODYSKIN Supplement
Other · Dietary Supplement
Lead sponsor
Clearstem Skincare
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response

NCT04255368
View directory record Official record
Conditions
Metabolism
Interventions
Water-soluble choline, Fat-soluble choline, No choline control
Other
Lead sponsor
Utah State University
Other
Eligibility
21 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 22, 2026, 10:41 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effects of Beverages on Food Liking

NCT03579043
View directory record Official record
Conditions
Obesity
Interventions
Nutritive Sweetener, Non-Nutritive Sweetener, Carbonated Water
Other
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

NCT01649869
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 4 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics

NCT02117869
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Low furanocoumarin hybrid grapefruit juice, Regular grapefruit juice, Water (control)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

NCT06366503
View directory record Official record
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Blue Ash, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Environmental Temperatures in Respiratory Control

NCT07470086
View directory record Official record
Conditions
Work of Breathing
Interventions
Thermoneutral temperature environment, Cold temperature environment, Hot temperature environment
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 22, 2026, 10:41 PM EDT
Withdrawn Not applicable Interventional

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

NCT00980551
View directory record Official record
Conditions
Retinoblastoma
Interventions
subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Different Anti-smoking Messages Among Chinese Young Adult Smokers and Nonsmokers

NCT06730646
View directory record Official record
Conditions
Smoking Prevention
Interventions
Health effects, Tobacco industry manipulation, Secondhand smoke, Mentral health, Social acceptability, Control
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 25 Years
Enrollment
1,541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Extension for 43USSA1812

NCT04595331
View directory record Official record
Conditions
Cheek, Wrinkle
Interventions
Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
21 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Encino, California • Redondo Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

NCT03490162
View directory record Official record
Conditions
Malaria
Interventions
DM1157, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 22, 2026, 10:41 PM EDT
Terminated Not applicable Interventional

Weekly Antepartum Testing in Women With BMI 30-40 and Neonatal Outcomes

NCT04180566
View directory record Official record
Conditions
Obesity Complicating Childbirth
Interventions
Ultrasound Examination, Antenatal Testing (biophysical profile)
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

NCT04649541
View directory record Official record
Conditions
Safety
Interventions
MRX-8, Placebo
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients

NCT02531594
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBIRT, HHC
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 22, 2026, 10:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Nutrient Sequencing in Healthy Adults

NCT07873437
View directory record Official record
Conditions
Pre Diabetes
Interventions
Finger Prick- Blood Glucose, Whole Blood Draw, Diet History Questionnaire, Physical Activity Assessment
Procedure · Behavioral
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Phase 3 Interventional

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

NCT05163288
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional

Post-incision Antimicrobial Wash vs C. Acnes in Shoulder Arthroplasty

NCT06831422
View directory record Official record
Conditions
Shoulder Arthroplasty, Positive C. Acnes Culture
Interventions
Povidone-Iodine, Hydrogen Peroxide, Xperience Antimicrobial Wash, Bacterial Cultures, Shoulder Arthroplasty
Device · Diagnostic Test · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Early Phase 1 Interventional

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

NCT06123286
View directory record Official record
Conditions
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Interventions
Tart Cherry, Omega 3 FA (Fish Oil)
Drug
Lead sponsor
Philip Chang
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 10:41 PM EDT